logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

HR+/HER2− mBC: add-on CDK4/6i boosts efficacy, toxicity in Italian meta-analysis

Benefits must be weighed against extended treatment duration, toxicities, and costs.